XML 78 R62.htm IDEA: XBRL DOCUMENT v3.5.0.1
Equity Instruments (Details)
9 Months Ended 12 Months Ended
Mar. 31, 2016
Jun. 30, 2015
Jun. 30, 2014
Luoxis Diagnostics [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Expected volatility 75.00%    
Expected volatility, minimum   79.00% 79.00%
Expected volatility, maximum   108.00% 82.00%
Risk free interest rate, Minimum 1.21% 1.62% 0.75%
Risk free interest rate, Maximum 1.90% 2.09% 1.53%
Dividend yield 0.00% 0.00% 0.00%
Vyrix Pharmaceuticals Inc [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Expected volatility, minimum     63.00%
Expected volatility, maximum     76.00%
Risk free interest rate, Minimum     0.90%
Risk free interest rate, Maximum     2.02%
Dividend yield     0.00%
Minimum [Member] | Luoxis Diagnostics [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Contractual term (years) 3 years 9 months 5 years 6 months 5 years
Minimum [Member] | Vyrix Pharmaceuticals Inc [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Contractual term (years)     5 years
Maximum [Member] | Luoxis Diagnostics [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Contractual term (years) 6 years 3 months 7 years 6 years 6 months
Maximum [Member] | Vyrix Pharmaceuticals Inc [Member]      
Assumptions Used To Determine Fair Value Options [Line Items]      
Contractual term (years)     6 years 6 months